Publications by authors named "L B Falco"

Introduction: we discuss the clinical case of a patient referred to our cardiology unit to evaluate the need for a pericardiectomy due to constrictive pericarditis.

Imaging: the echocardiographic assessment confirmed all diagnostic criteria for constrictive pericarditis; however, we conducted a cardiac MRI before referring the patient to the cardiac surgeon. This imaging technique not only confirmed the constrictive pathophysiology but also indicated extensive pericardial inflammation, consistent with transient constriction.

View Article and Find Full Text PDF

Pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (PH-HFpEF) represents a frequent form of PH related to left ventricular dysfunction. The pathophysiology of PH-HFpEF is intricate, and varied and includes vascular, cardiac, and pulmonary factors that contribute synergistically to developing this clinical syndrome. Improved knowledge of the pathophysiology of PH-HFpEF has paved the way for the use of new drugs such as angiotensin receptor neprilysin inhibitors (ARNIs), non-steroidal mineral corticoid receptor antagonist (nsMRA), sodium-glucose cotransporter inhibitors (SGLT2is), levosimendan, and glucagon-like peptide 1 (GLP-1) agonists.

View Article and Find Full Text PDF
Article Synopsis
  • - A 37-year-old woman with a balanced reciprocal translocation was found to have a high-risk non-invasive prenatal screening test indicating potential chromosome 18 abnormalities during her 13th week of pregnancy.
  • - Advanced techniques including cytogenetic analysis, FISH, and SNP-array were used to analyze her amniotic cells, revealing duplications on chromosome 18 and chromosome 9, suggesting aneuploidies.
  • - The study emphasizes the importance of using a combination of NIPT and detailed cytogenetic approaches to accurately detect and confirm chromosomal anomalies in high-risk pregnancies.
View Article and Find Full Text PDF

Background: Sodium-Glucose Cotransporter-2 inhibitors (SGLT2i) represent a deep revolution of the therapeutic approach to heart failure (HF), preventing its insurgence but also improving the management of the disease and slowing its natural progression. To date, few studies have explored the effectiveness of SGLT2i and, in particular, Dapagliflozin in a real-world population. Therefore, in this observational prospective study, we evaluated Dapagliflozin's effectiveness in a real-world HF population categorized in the different hemodynamic profiles.

View Article and Find Full Text PDF